These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

818 related articles for article (PubMed ID: 28559413)

  • 41. Triple-negative breast cancer: making the most of a misnomer.
    McCarthy N; Mitchell G; Bilous M; Wilcken N; Lindeman GJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):145-55. PubMed ID: 22524573
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.
    Rayson D; Lupichuk S; Potvin K; Dent S; Shenkier T; Dhesy-Thind S; Ellard SL; Prady C; Salim M; Farmer P; Allo G; Tsao MS; Allan A; Ludkovski O; Bonomi M; Tu D; Hagerman L; Goodwin R; Eisenhauer E; Bradbury P
    Breast Cancer Res Treat; 2016 May; 157(1):109-16. PubMed ID: 27116183
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
    Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
    Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tissue Microarray Immunohistochemical Staining for Androgen Receptor in Breast Cancer in a Ghanaian Cohort.
    Duduyemi BM; Ayibor WG; Agyemang-Yeboah F
    Ann Afr Med; 2024 Jul; 23(3):452-458. PubMed ID: 39034572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent Progress in Triple Negative Breast Cancer Research.
    Mouh FZ; Mzibri ME; Slaoui M; Amrani M
    Asian Pac J Cancer Prev; 2016; 17(4):1595-608. PubMed ID: 27221827
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular stratification of triple-negative breast cancers.
    Perou CM
    Oncologist; 2011; 16 Suppl 1():61-70. PubMed ID: 21278442
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
    Moy B; Rumble RB; Come SE; Davidson NE; Di Leo A; Gralow JR; Hortobagyi GN; Yee D; Smith IE; Chavez-MacGregor M; Nanda R; McArthur HL; Spring L; Reeder-Hayes KE; Ruddy KJ; Unger PS; Vinayak S; Irvin WJ; Armaghani A; Danso MA; Dickson N; Turner SS; Perkins CL; Carey LA
    J Clin Oncol; 2021 Dec; 39(35):3938-3958. PubMed ID: 34324366
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinicopathological comparison of triple negative breast cancers with non-triple negative breast cancers in a hospital in North India.
    Nabi MG; Ahangar A; Wahid MA; Kuchay S
    Niger J Clin Pract; 2015; 18(3):381-6. PubMed ID: 25772923
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease.
    Kalimutho M; Parsons K; Mittal D; López JA; Srihari S; Khanna KK
    Trends Pharmacol Sci; 2015 Dec; 36(12):822-846. PubMed ID: 26538316
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Mehlich D; Marusiak AA
    Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Triple-negative breast cancer: present challenges and new perspectives.
    Podo F; Buydens LM; Degani H; Hilhorst R; Klipp E; Gribbestad IS; Van Huffel S; van Laarhoven HW; Luts J; Monleon D; Postma GJ; Schneiderhan-Marra N; Santoro F; Wouters H; Russnes HG; Sørlie T; Tagliabue E; Børresen-Dale AL;
    Mol Oncol; 2010 Jun; 4(3):209-29. PubMed ID: 20537966
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Triple-negative breast cancers and the human mammary epithelial cell hierarchy.
    Ganesan S; Karantza V; Oza J; Toppmeyer D
    Breast Dis; 2010; 32(1-2):49-61. PubMed ID: 22045329
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs.
    Oh YJ; Park SY; Seo YH
    Oncol Rep; 2018 Apr; 39(4):1775-1782. PubMed ID: 29436674
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytologic features of triple-negative breast carcinoma.
    Bonzanini M; Morelli L; Bonandini EM; Leonardi E; Pertile R; Dalla Palma P
    Cancer Cytopathol; 2012 Dec; 120(6):401-9. PubMed ID: 22833438
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
    Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
    BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer.
    Singel SM; Cornelius C; Batten K; Fasciani G; Wright WE; Lum L; Shay JW
    Clin Cancer Res; 2013 Apr; 19(8):2061-70. PubMed ID: 23479679
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of treatment outcomes of triple-negative breast cancer.
    Cinkaya A; Akin M; Sengul A
    J Cancer Res Ther; 2016; 12(1):150-4. PubMed ID: 27072229
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A.
    Szarc Vel Szic K; Declerck K; Crans RAJ; Diddens J; Scherf DB; Gerhäuser C; Vanden Berghe W
    Oncotarget; 2017 Jun; 8(25):40434-40453. PubMed ID: 28467815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.